Table 1. Patient and treatment... | American Society of Hematology

Table 1.

Patient and treatment characteristics (n = 110, except where indicated)

Parameter at diagnosis	No. of patients	%
Age ≥ 60 y	33	30
Stage III	64	58
PCL	6	5
B substage (n = 104)	11	11
IgA isotype (n = 108)	23	21
λ light chain (n = 108)	36	33
β₂m ≥ 2.5 mg/L	79	71
CRP ≥ 6 mg/L (n = 102)	43	42
Bone marrow plasmacytosis > 25% (n = 108)	74	69
Albumin ≤ 35 g/L (n = 108)	30	28
Type of HDT
HDM 140 alone	5	5
1 autotransplant	62	56
Tandem autotransplants	20	18
1 HDT at diagnosis + 1 autotransplant at first relapse	21	19
Other type^*	2	2

Parameter at diagnosis	No. of patients	%
Age ≥ 60 y	33	30
Stage III	64	58
PCL	6	5
B substage (n = 104)	11	11
IgA isotype (n = 108)	23	21
λ light chain (n = 108)	36	33
β₂m ≥ 2.5 mg/L	79	71
CRP ≥ 6 mg/L (n = 102)	43	42
Bone marrow plasmacytosis > 25% (n = 108)	74	69
Albumin ≤ 35 g/L (n = 108)	30	28
Type of HDT
HDM 140 alone	5	5
1 autotransplant	62	56
Tandem autotransplants	20	18
1 HDT at diagnosis + 1 autotransplant at first relapse	21	19
Other type^*	2	2

PCL indicates primary plasma cell leukemia; HDT, high-dose therapy; HDM 140, high-dose melphalan 140 mg/m².

One allogeneic bone marrow transplant and one autotransplant followed by an allogeneic transplant.